| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHPSYC.55.10.918 |
| P698 | PubMed publication ID | 9783563 |
| P50 | author | Donald F. Klein | Q2843570 |
| P2093 | author name string | S Davies | |
| M R Liebowitz | |||
| R Campeas | |||
| B A Fallon | |||
| F R Schneier | |||
| R Marshall | |||
| D Goetz | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clomipramine | Q58713 |
| obsessive-compulsive disorder | Q178190 | ||
| placebo | Q269829 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 918-924 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. | |
| P478 | volume | 55 |
| Q38004948 | A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder |
| Q36276544 | A review of antipsychotics in the treatment of obsessive compulsive disorder |
| Q35936259 | A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation |
| Q37407571 | Alternative routes to oral antidepressant therapy: case vignette and literature review |
| Q36765772 | An update on the pharmacological treatment of obsessive-compulsive disorder |
| Q27009995 | Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders |
| Q38174158 | Commonly asked questions in the treatment of obsessive-compulsive disorder |
| Q22306025 | Current and potential pharmacological treatments for obsessive-compulsive disorder |
| Q22305853 | Current trends in drug treatment of obsessive–compulsive disorder |
| Q37610143 | Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis |
| Q24635508 | Drug treatment of obsessive-compulsive disorder |
| Q38174649 | Emerging drugs to treat obsessive-compulsive disorder |
| Q34465555 | Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology |
| Q53091817 | Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. |
| Q89079751 | Functional and Structural Neural Changes in Obsessive-compulsive Disorder after Pharmacotherapy |
| Q31032734 | Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder |
| Q35169603 | How to treat OCD in patients with Tourette syndrome. |
| Q36635618 | Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder |
| Q44659894 | Intravenous Clomipramine in Severe and Refractory Obsessive-Compulsive Disorder |
| Q37273000 | Intravenous anti-obsessive agents: a review |
| Q35673399 | Intravenous antidepressants: a review |
| Q32078743 | Intravenous clomipramine decreases excitability of human motor cortex. A study with paired magnetic stimulation |
| Q36200991 | Minority participation in randomized controlled trials for obsessive-compulsive disorder |
| Q56910158 | Obsessive-compulsive disorder |
| Q36058933 | Obsessive-compulsive disorder: a critical review of therapeutic perspectives |
| Q36253232 | Personality disorders in hypochondriasis: prevalence and comparison with two anxiety disorders |
| Q37893636 | Pharmacological management of treatment-resistant obsessive-compulsive disorder |
| Q24243827 | Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders |
| Q35686859 | Pharmacotherapy of anxiety disorders: a critical review |
| Q38057736 | Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond |
| Q58113540 | Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time |
| Q34228150 | Psychopharmacology of anxiety disorders. |
| Q35212987 | Psychotherapy and medication management strategies for obsessive-compulsive disorder |
| Q38070934 | Quality of life in obsessive compulsive disorder |
| Q39325451 | Resistance and refractoriness in obsessive-compulsive disorder |
| Q34108465 | Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder |
| Q38536162 | Treating OCD: what to do when first-line therapies fail |
| Q28066707 | Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies |
| Q22305681 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders |
| Q34865036 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision |
Search more.